NASDAQ:AGIOAgios Pharmaceuticals Stock Price, Forecast & News

Agios Pharmaceuticals' stock was trading at $40.87 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AGIO shares have increased by 23.3% and is now trading at $50.40. View which stocks have been most impacted by Coronavirus.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Agios Pharmaceuticals.

Agios Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Agios Pharmaceuticals.

Agios Pharmaceuticals Inc (NASDAQ:AGIO) announced its quarterly earnings results on Thursday, April, 30th. The biopharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.67) by $1.08. The biopharmaceutical company had revenue of $87.10 million for the quarter, compared to analysts' expectations of $31.12 million. Agios Pharmaceuticals had a negative net margin of 205.20% and a negative return on equity of 63.85%. Agios Pharmaceuticals's revenue for the quarter was up 188.4% on a year-over-year basis. During the same quarter last year, the company earned ($1.59) earnings per share. View Agios Pharmaceuticals' earnings history.

14 brokerages have issued 12-month target prices for Agios Pharmaceuticals' stock. Their forecasts range from $49.00 to $82.00. On average, they expect Agios Pharmaceuticals' share price to reach $69.67 in the next twelve months. This suggests a possible upside of 38.2% from the stock's current price. View analysts' price targets for Agios Pharmaceuticals.

Media stories about AGIO stock have been trending very negative this week, InfoTrie Sentiment reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Agios Pharmaceuticals earned a news impact score of -3.6 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about Agios Pharmaceuticals.

Some companies that are related to Agios Pharmaceuticals include Sarepta Therapeutics (SRPT), Teva Pharmaceutical Industries (TEVA), GRIFOLS S A/S (GRFS), GALAPAGOS NV/S (GLPG), Catalent (CTLT), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Elanco Animal Health (ELAN), Ionis Pharmaceuticals (IONS), ACADIA Pharmaceuticals (ACAD), Dr.Reddy's Laboratories (RDY), Mylan (MYL), Perrigo (PRGO), Ascendis Pharma A/S (ASND) and Bausch Health Companies (BHC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Celgene (CELG), Alibaba Group (BABA), bluebird bio (BLUE), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Micron Technology (MU) and NVIDIA (NVDA).

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

Agios Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.01%) and Carroll Financial Associates Inc. (0.00%). Company insiders that own Agios Pharmaceuticals stock include Carman Alenson, Christopher Bowden, Corp /De/ Celgene, David P Schenkein, Jacqualyn A Fouse, John Maraganore, Scott Biller and Steven L Hoerter. View institutional ownership trends for Agios Pharmaceuticals.

AGIO stock was sold by a variety of institutional investors in the last quarter, including Carroll Financial Associates Inc.. Company insiders that have sold Agios Pharmaceuticals company stock in the last year include Carman Alenson, and Christopher Bowden. View insider buying and selling activity for Agios Pharmaceuticals.

AGIO stock was purchased by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. Company insiders that have bought Agios Pharmaceuticals stock in the last two years include Corp /De/ Celgene, David P Schenkein, and Jacqualyn A Fouse. View insider buying and selling activity for Agios Pharmaceuticals.

Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AGIO stock can currently be purchased for approximately $50.40.

Agios Pharmaceuticals has a market capitalization of $3.47 billion and generates $117.91 million in revenue each year. The biopharmaceutical company earns $-411,470,000.00 in net income (profit) each year or ($6.86) on an earnings per share basis. Agios Pharmaceuticals employs 482 workers across the globe.

The official website for Agios Pharmaceuticals is www.agios.com.

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected]